Hubbry Logo
ProgesteroneProgesteroneMain
Open search
Progesterone
Community hub
Progesterone
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Progesterone
Progesterone
from Wikipedia

Progesterone
The chemical structure of progesterone
A ball-and-stick model of progesterone.
Names
IUPAC name
Pregn-4-ene-3,20-dione[2][3]
Systematic IUPAC name
(1S,3aS,3bS,9aR,9bS,11aS)-1-Acetyl-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[a]phenanthren-7-one
Other names
P4;[1] Pregnenedione
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
DrugBank
ECHA InfoCard 100.000.318 Edit this at Wikidata
KEGG
UNII
  • InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1 ☒N
    Key: RJKFOVLPORLFTN-LEKSSAKUSA-N checkY
  • CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
Properties
C21H30O2
Molar mass 314.469 g/mol
Density 1.171
Melting point 126
log P 4.04[4]
Pharmacology
G03DA04 (WHO)
By mouth, topical/transdermal, vaginal, intramuscular injection, subcutaneous injection, subcutaneous implant
Pharmacokinetics:
OMP: <10%[5][6]
Albumin: 80%
CBG: 18%
SHBG: <1%
• Free: 1–2%[7][8]
Hepatic (CYP2C19, CYP3A4, CYP2C9, 5α-reductase, 3α-HSDTooltip 3α-hydroxysteroid dehydrogenase, 17α-hydroxylase, 21-hydroxylase, 20α-HSDTooltip 20α-hydroxysteroid dehydrogenase)[9][10]
OMP: 16–18 hours[5][6][11]
IM: 22–26 hours[6][12]
SC: 13–18 hours[12]
Renal
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Progesterone (/prˈɛstərn/ ; P4) is an endogenous steroid and progestogen sex hormone involved in the menstrual cycle, pregnancy, and embryogenesis of humans and other species.[1][13] It belongs to a group of steroid hormones called the progestogens[13] and is the major progestogen in the body. Progesterone has a variety of important functions in the body. It is also a crucial metabolic intermediate in the production of other endogenous steroids, including the sex hormones and the corticosteroids, and plays an important role in brain function as a neurosteroid.[14]

In addition to its role as a natural hormone, progesterone is also used as a medication, such as in combination with estrogen for contraception, to reduce the risk of uterine or cervical cancer, in hormone replacement therapy, and in feminizing hormone therapy.[15] It was first prescribed in 1934.[16]

Biological activity

[edit]

Progesterone is the most important progestogen in the body. As a potent agonist of the nuclear progesterone receptor (nPR) (with an affinity of KD = 1 nM), the resulting effects on ribosomal transcription play a major role in regulation of female reproduction.[13][17] In addition, progesterone is an agonist of the more recently discovered membrane progesterone receptors (mPRs),[18] of which the expression has regulation effects in reproduction function (oocyte maturation, labor, and sperm motility) and cancer, although additional research is required to further define the roles.[19] It also functions as a ligand of the PGRMC1 (progesterone receptor membrane component 1) which impacts tumor progression, metabolic regulation, and viability control of nerve cells.[20][21][22] Moreover, progesterone is also known to be an antagonist of the sigma σ1 receptor,[23][24] a negative allosteric modulator of nicotinic acetylcholine receptors,[14] and a potent antagonist of the mineralocorticoid receptor (MR).[25] Progesterone prevents MR activation by binding to this receptor with an affinity exceeding even those of aldosterone, and glucocorticoids such as cortisol and corticosterone,[25] and it produces antimineralocorticoid effects, such as natriuresis, at physiological concentrations.[26] Progesterone also binds to, and behaves as a partial agonist of, the glucocorticoid receptor (GR), albeit with very low potency (EC50 >100-fold less relative to cortisol).[27][28]

Through its neurosteroid active metabolites, such as 5α-dihydroprogesterone and allopregnanolone, progesterone acts indirectly as a positive allosteric modulator of the GABAA receptor.[29]

Progesterone and some of its metabolites, such as 5β-dihydroprogesterone, are agonists of the pregnane X receptor (PXR),[30] albeit weakly so (EC50 >10 μM).[31] In accordance, progesterone induces several hepatic cytochrome P450 enzymes,[32] such as CYP3A4,[33][34] especially during pregnancy when concentrations are much higher than usual.[35] Perimenopausal women have been found to have greater CYP3A4 activity relative to men and postmenopausal women, and it has been inferred that this may be due to the higher progesterone levels present in perimenopausal women.[33]

Progesterone modulates the activity of CatSper (cation channels of sperm) voltage-gated Ca2+ channels. Since eggs release progesterone, sperm may use progesterone as a homing signal to swim toward eggs (chemotaxis). As a result, it has been suggested that substances that block the progesterone binding site on CatSper channels could potentially be used in male contraception.[36][37]

Biological function

[edit]
During the menstrual cycle, levels of estradiol (an estrogen) vary by 200 percent. Levels of progesterone vary by over 1200 percent.[38]

Hormonal interactions

[edit]

Progesterone has a number of physiological effects that are amplified in the presence of estrogens. Estrogens through estrogen receptors (ERs) induce or upregulate the expression of the PR.[39] One example of this is in breast tissue, where estrogens allow progesterone to mediate lobuloalveolar development.[40][41][42]

Elevated levels of progesterone potently reduce the sodium-retaining activity of aldosterone, resulting in natriuresis and a reduction in extracellular fluid volume. Progesterone withdrawal, on the other hand, is associated with a temporary increase in sodium retention (reduced natriuresis, with an increase in extracellular fluid volume) due to the compensatory increase in aldosterone production, which combats the blockade of the mineralocorticoid receptor by the previously elevated level of progesterone.[43]

Early sexual differentiation

[edit]

Placental progesterone can be converted into 5α-dihydrotestosterone (DHT), a potent androgen that is responsible for the development of male genitalia.[44] This can be done both by conversion into testosterone, which is then converted to DHT, and via the androgen backdoor pathway, which is particularly important for fetal development.[45] Progesterone is the precursor for both pathways and therefore plays a key role in sexual differentiation.[46][47]

Reproductive system

[edit]
Micrograph showing changes to the endometrium due to progesterone (decidualization) H&E stain

Progesterone has key effects via non-genomic signalling on human sperm as they migrate through the female reproductive tract before fertilization occurs, though the receptor(s) as yet remain unidentified.[48] Detailed characterisation of the events occurring in sperm in response to progesterone has elucidated certain events including intracellular calcium transients and maintained changes,[49] slow calcium oscillations,[50] now thought to possibly regulate motility.[51] It is produced by the ovaries.[52] Progesterone has also been shown to demonstrate effects on octopus spermatozoa.[53]

Progesterone is sometimes called the "hormone of pregnancy",[54] and it has many roles relating to the development of the fetus:

  • Progesterone converts the endometrium to its secretory stage to prepare the uterus for implantation. At the same time progesterone affects the vaginal epithelium and cervical mucus, making it thick and impenetrable to sperm. Progesterone is anti-mitogenic in endometrial epithelial cells, and as such, mitigates the tropic effects of estrogen.[55] If pregnancy does not occur, progesterone levels will decrease, leading to menstruation. Normal menstrual bleeding is progesterone-withdrawal bleeding. If ovulation does not occur, and the corpus luteum does not develop, levels of progesterone may be low, leading to anovulatory dysfunctional uterine bleeding.
  • During implantation and gestation, progesterone appears to decrease the maternal immune response to allow for the acceptance of the pregnancy.[56]
  • Progesterone decreases contractility of the uterine smooth muscle.[54] This effect contributes to prevention of preterm labor.[56] Studies have shown that in individuals who are pregnant with a single fetus, asymptomatic in the prenatal stage, and at a high risk of giving pre-term birth spontaneously, vaginal progesterone medication has been found to be effective in preventing spontaneous pre-term birth. Individuals who are at a high risk of giving pre-term birth spontaneously are those who have a short cervix of less than 25 mm or have previously given pre-term birth spontaneously. Although pre-term births are generally considered to be less than 37 weeks, these studies found that vaginal progesterone is associated with fewer pre-term births of less than 34 weeks.[57]
  • A drop in progesterone levels is possibly one step that facilitates the onset of labor.[citation needed]
  • In addition, progesterone inhibits lactation during pregnancy. The fall in progesterone levels following delivery is one of the triggers for milk production.[citation needed]

The fetus metabolizes placental progesterone in the production of adrenal steroids.[45]

Breasts

[edit]

Lobuloalveolar development

[edit]

Progesterone plays an important role in breast development. In conjunction with prolactin, it mediates lobuloalveolar maturation of the mammary glands during pregnancy to allow for milk production, and thus lactation and breastfeeding of offspring following parturition (childbirth).[58] Estrogen induces expression of the progesterone receptors (PR) in breast tissue, and hence progesterone is dependent on estrogen to mediate lobuloalveolar development.[40][41][42] It has been found that RANKLTooltip Receptor activator of nuclear factor kappa-B ligand is a critical downstream mediator of progesterone-induced lobuloalveolar maturation.[59] RANKL knockout mice show an almost identical mammary phenotype to PR knockout mice, including normal mammary ductal development, but complete failure of the development of lobuloalveolar structures.[59]

Ductal development

[edit]

Though to a far lesser extent than estrogen, which is the major mediator of mammary ductal development (via the ERα),[60][61] progesterone may also be involved in ductal development of the mammary glands to some extent.[62] PR knockout mice or mice treated with the PR antagonist mifepristone show delayed although otherwise normal mammary ductal development at puberty.[62] In addition, mice modified to have overexpression of PRA display ductal hyperplasia,[59] and progesterone induces ductal growth in the mouse mammary gland.[62] Progesterone mediates ductal development mainly via induction of the expression of amphiregulin, the same growth factor that estrogen primarily induces the expression of to mediate ductal development.[62] These animal findings suggest that, while not essential for full mammary ductal development, progesterone seems to play a potentiating or accelerating role in estrogen-mediated mammary ductal development.[62]

Breast cancer risk

[edit]

Progesterone also appears to be involved in the pathophysiology of breast cancer, though its role, and whether it is a promoter or inhibitor of breast cancer risk, has not been fully elucidated.[63][64] Most progestins, or synthetic progestogens, like medroxyprogesterone acetate, have been found to increase the risk of breast cancer in postmenopausal people in combination with estrogen as a component of menopausal hormone therapy.[65][64] The combination of natural oral progesterone or the atypical progestin dydrogesterone with estrogen has been associated with less risk of breast cancer than progestins plus estrogen.[66][67][68] However, this may simply be an artifact of the low progesterone levels produced with oral progesterone.[63][69] More research is needed on the role of progesterone in breast cancer.[64]

Skin health

[edit]

The estrogen receptor, as well as the progesterone receptor, have been detected in the skin, including in keratinocytes and fibroblasts.[70][71] At menopause and thereafter, decreased levels of female sex hormones result in atrophy, thinning, and increased wrinkling of the skin, and a reduction in skin elasticity, firmness, and strength.[70][71] These skin changes constitute an acceleration in skin aging and are the result of decreased collagen content, irregularities in the morphology of epidermal skin cells, decreased ground substance between skin fibers, and reduced capillaries and blood flow.[70][71] The skin also becomes more dry during menopause, as a result of reduced skin hydration and surface lipids (sebum production).[70] Along with chronological aging and photoaging, estrogen deficiency in menopause is one of the three main factors that predominantly influences skin aging.[70]

Hormone replacement therapy, consisting of systemic treatment with estrogen alone or in combination with a progestogen, has well-documented and considerable beneficial effects on the skin of postmenopausal people.[70][71] These benefits include increased skin collagen content, skin thickness and elasticity, and skin hydration and surface lipids.[70][71] Topical estrogen has been found to have similar beneficial effects on the skin.[70] In addition, a study has found that topical 2% progesterone cream significantly increases skin elasticity and firmness and observably decreases wrinkles in peri- and postmenopausal people.[71] Skin hydration and surface lipids, on the other hand, did not significantly change with topical progesterone.[71]

These findings suggest that progesterone, like estrogen, also has beneficial effects on the skin and may be independently protective against skin aging.[71]

Sexuality

[edit]

Libido

[edit]

Progesterone and its neurosteroid active metabolite, allopregnanolone, appear to be importantly involved in libido in females.[72]

Homosexuality

[edit]

Dr. Diana Fleischman, of the University of Portsmouth, and colleagues looked for a relationship between progesterone and sexual attitudes in 92 women. Their research, published in the Archives of Sexual Behavior found that women who had higher levels of progesterone scored higher on a questionnaire measuring homoerotic motivation. They also found that men who had high levels of progesterone were more likely to have higher homoerotic motivation scores after affiliative priming compared to men with low levels of progesterone.[73][74][75][76]

Nervous system

[edit]

Progesterone, like pregnenolone and dehydroepiandrosterone (DHEA), belongs to an important group of endogenous steroids called neurosteroids. It can be metabolized within all parts of the central nervous system.[77]

Neurosteroids are neuromodulators and are neuroprotective, neurogenic, and regulate neurotransmission and myelination.[78] The effects of progesterone as a neurosteroid are mediated predominantly through its interactions with non-nuclear PRs, namely the mPRs and PGRMC1, as well as certain other receptors, such as the σ1 and nACh receptors.[79]

Brain damage

[edit]

Previous studies have shown that progesterone supports the normal development of neurons in the brain, and that the hormone has a protective effect on damaged brain tissue. It has been observed in animal models that females have reduced susceptibility to traumatic brain injury, and this protective effect has been hypothesized to be caused by increased circulating levels of estrogen and progesterone in females.[80]

Proposed mechanism

[edit]

The mechanism of progesterone protective effects may be the reduction of inflammation that follows brain trauma and hemorrhage.[81][82]

Damage incurred by traumatic brain injury is believed to be caused in part by mass depolarization leading to excitotoxicity. One way in which progesterone helps to alleviate some of this excitotoxicity is by blocking the voltage-dependent calcium channels that trigger neurotransmitter release.[83] It does so by manipulating the signaling pathways of transcription factors involved in this release. Another method for reducing the excitotoxicity is by up-regulating the GABAA, a widespread inhibitory neurotransmitter receptor.[84]

Progesterone has also been shown to prevent apoptosis in neurons, a common consequence of brain injury. It does so by inhibiting enzymes involved in the apoptosis pathway specifically concerning the mitochondria, such as activated caspase-3 and cytochrome c.[85]

Not only does progesterone help prevent further damage, it has also been shown to aid in neuroregeneration.[86] One of the serious effects of traumatic brain injury includes edema. Animal studies show that progesterone treatment leads to a decrease in edema levels by increasing the concentration of macrophages and microglia sent to the injured tissue.[83][87] This was observed in the form of reduced leakage from the blood brain barrier in secondary recovery in progesterone treated rats. In addition, progesterone was observed to have antioxidant properties, reducing the concentration of oxygen free radicals faster than without.[84] There is also evidence that the addition of progesterone can also help remyelinate damaged axons due to trauma, restoring some lost neural signal conduction.[84] Another way progesterone aids in regeneration includes increasing the circulation of endothelial progenitor cells in the brain. This aids the growth of new vasculature around scar tissue, helping to repair the area of insult.[88]

Addiction

[edit]

Progesterone enhances the function of serotonin receptors in the brain, so an excess or deficit of progesterone has the potential to result in significant neurochemical issues. This provides an explanation for why some people resort to substances that enhance serotonin activity such as nicotine, alcohol, and cannabis when their progesterone levels fall below optimal levels.[89]

  • Sex differences in hormone levels may induce women to respond differently than men to nicotine. When women undergo cyclic changes or different hormonal transition phases (menopause, pregnancy, adolescence), there are changes in their progesterone levels.[90] Therefore, females have an increased biological vulnerability to nicotine's reinforcing effects compared to males, and progesterone may be used to counter this enhanced vulnerability. This information supports the idea that progesterone can affect behavior.[89]
  • Similar to nicotine, cocaine also increases the release of dopamine in the brain. The neurotransmitter is involved in the reward center and is one of the main neurotransmitters involved with substance abuse and reliance. In a study of cocaine users, it was reported that progesterone reduced craving and the feeling of being stimulated by cocaine. Thus, progesterone was suggested as an agent that decreases cocaine craving by reducing the dopaminergic properties of the drug.[91]

Societal

[edit]

In a 2012 University of Amsterdam study of 120 women, the women's luteal phase (higher levels of progesterone, and increasing levels of estrogen) was correlated with a lower level of competitive behavior in gambling and math contest scenarios, while their premenstrual phase (sharply-decreasing levels of progesterone, and decreasing levels of estrogen) was correlated with a higher level of competitive behavior.[92]

Other effects

[edit]
  • Progesterone also has a role in skin elasticity and bone strength, in respiration, in nerve tissue and in female sexuality, and the presence of progesterone receptors in certain muscle and fat tissue may hint at a role in sexually dimorphic proportions of those.[93]
  • During pregnancy, progesterone is said to decrease uterine irritability.[94]
  • During pregnancy, progesterone helps to suppress immune responses of the mother to fetal antigens, thus preventing rejection of the fetus.[94]
  • Progesterone raises epidermal growth factor-1 (EGF-1) levels, a factor often used to induce proliferation of stem cells, and used to sustain stem cell cultures.[95]
  • Progesterone increases core temperature (thermogenic function) during ovulation.[96][97]
  • Progesterone reduces spasm and relaxes smooth muscle. Bronchi are widened and mucus regulated. (PRs are widely present in submucosal tissue.)[98]
  • Progesterone acts as an anti-inflammatory agent and regulates the immune response.[99]
  • Progesterone reduces gallbladder activity.[100]
  • Progesterone normalizes blood clotting and vascular tone, zinc and copper levels, cell oxygen levels, and use of fat stores for energy.[citation needed]
  • Progesterone may affect gum health, increasing risk of gingivitis (gum inflammation).[101]
  • Progesterone appears to prevent endometrial cancer (involving the uterine lining) by regulating the effects of estrogen.
  • Progesterone plays an important role in the signaling of insulin release and pancreatic function, and it may affect the susceptibility to diabetes or gestational diabetes.[102][103]
  • Progesterone levels in the blood were found to be lower in those who had higher weight and higher BMI among those who became pregnant through in vitro fertilization.[104]
  • Current data shows that micronized progesterone, which is chemically identical to the progesterone produced in the human body, in combination with estrogen in menopausal hormone therapy does not seem to have significant effects on venous thromboembolism (blood clots in veins) and ischemic stroke (lack of blood flow to the brain due to blockage of a blood vessel that supplies the brain). However, more studies need to be conducted to see whether or not micronized progesterone alone or in combined menopausal hormone therapy changes the risk of myocardial infarctions (heart attacks).[105]
  • There have not been any studies done yet on the effects of micronized progesterone on hair loss due to menopause.[106]
  • Despite suggestions for using hormone therapy to prevent loss of muscle mass in post-menopausal individuals (age 50+), menopausal hormone therapy involving either estrogen alone, or estrogen and progesterone combined, has not been found to preserve muscle mass.[107] Menopausal hormone therapy also does not result in body weight reduction, BMI reduction, or change in glucose metabolism.[108]

Biochemistry

[edit]

Biosynthesis

[edit]
Steroidogenesis, showing progesterone among the progestogens (yellow area)[109]

In mammals, progesterone, like all other steroid hormones, is synthesized from pregnenolone, which itself is derived from cholesterol.[citation needed]

Cholesterol undergoes double oxidation to produce 22R-hydroxycholesterol and then 20α,22R-dihydroxycholesterol. This vicinal diol is then further oxidized with loss of the side chain starting at position C22 to produce pregnenolone. This reaction is catalyzed by cytochrome P450scc.[citation needed]

The conversion of pregnenolone to progesterone takes place in two steps. First, the 3β-hydroxyl group is oxidized to a keto group and second, the double bond is moved to C4, from C5 through a keto/enol tautomerization reaction.[110] This reaction is catalyzed by 3β-hydroxysteroid dehydrogenase/δ5-4-isomerase.[citation needed]

Progesterone in turn is the precursor of the mineralocorticoid aldosterone, and after conversion to 17α-hydroxyprogesterone, of cortisol and androstenedione. Androstenedione can be converted to testosterone, estrone, and estradiol, highlighting the critical role of progesterone in testosterone synthesis.[citation needed]

Pregnenolone and progesterone can also be synthesized by yeast.[111]

Approximately 30 mg of progesterone is secreted from the ovaries per day in reproductive-age women, while the adrenal glands produce about 1 mg of progesterone per day.[112]

Production rates, secretion rates, clearance rates, and blood levels of major sex hormones
Sex Sex hormone Reproductive
phase
Blood
production rate
Gonadal
secretion rate
Metabolic
clearance rate
Reference range (serum levels)
SI units Non-SI units
Men Androstenedione
2.8 mg/day 1.6 mg/day 2200 L/day 2.8–7.3 nmol/L 80–210 ng/dL
Testosterone
6.5 mg/day 6.2 mg/day 950 L/day 6.9–34.7 nmol/L 200–1000 ng/dL
Estrone
150 μg/day 110 μg/day 2050 L/day 37–250 pmol/L 10–70 pg/mL
Estradiol
60 μg/day 50 μg/day 1600 L/day <37–210 pmol/L 10–57 pg/mL
Estrone sulfate
80 μg/day Insignificant 167 L/day 600–2500 pmol/L 200–900 pg/mL
Women Androstenedione
3.2 mg/day 2.8 mg/day 2000 L/day 3.1–12.2 nmol/L 89–350 ng/dL
Testosterone
190 μg/day 60 μg/day 500 L/day 0.7–2.8 nmol/L 20–81 ng/dL
Estrone Follicular phase 110 μg/day 80 μg/day 2200 L/day 110–400 pmol/L 30–110 pg/mL
Luteal phase 260 μg/day 150 μg/day 2200 L/day 310–660 pmol/L 80–180 pg/mL
Postmenopause 40 μg/day Insignificant 1610 L/day 22–230 pmol/L 6–60 pg/mL
Estradiol Follicular phase 90 μg/day 80 μg/day 1200 L/day <37–360 pmol/L 10–98 pg/mL
Luteal phase 250 μg/day 240 μg/day 1200 L/day 699–1250 pmol/L 190–341 pg/mL
Postmenopause 6 μg/day Insignificant 910 L/day <37–140 pmol/L 10–38 pg/mL
Estrone sulfate Follicular phase 100 μg/day Insignificant 146 L/day 700–3600 pmol/L 250–1300 pg/mL
Luteal phase 180 μg/day Insignificant 146 L/day 1100–7300 pmol/L 400–2600 pg/mL
Progesterone Follicular phase 2 mg/day 1.7 mg/day 2100 L/day 0.3–3 nmol/L 0.1–0.9 ng/mL
Luteal phase 25 mg/day 24 mg/day 2100 L/day 19–45 nmol/L 6–14 ng/mL
Notes and sources
Notes: "The concentration of a steroid in the circulation is determined by the rate at which it is secreted from glands, the rate of metabolism of precursor or prehormones into the steroid, and the rate at which it is extracted by tissues and metabolized. The secretion rate of a steroid refers to the total secretion of the compound from a gland per unit time. Secretion rates have been assessed by sampling the venous effluent from a gland over time and subtracting out the arterial and peripheral venous hormone concentration. The metabolic clearance rate of a steroid is defined as the volume of blood that has been completely cleared of the hormone per unit time. The production rate of a steroid hormone refers to entry into the blood of the compound from all possible sources, including secretion from glands and conversion of prohormones into the steroid of interest. At steady state, the amount of hormone entering the blood from all sources will be equal to the rate at which it is being cleared (metabolic clearance rate) multiplied by blood concentration (production rate = metabolic clearance rate × concentration). If there is little contribution of prohormone metabolism to the circulating pool of steroid, then the production rate will approximate the secretion rate." Sources: See template.

Distribution

[edit]

Progesterone binds extensively to plasma proteins, including albumin (50‍–‍54%) and transcortin (43‍–‍48%).[113] It has similar affinity for albumin relative to the PR.[17]

Metabolism

[edit]

The metabolism of progesterone is rapid and extensive, and it occurs mainly in the liver,[114][115][116] though enzymes that metabolize progesterone are also expressed widely in the brain, skin, and various other extrahepatic tissues.[77][117] Progesterone has an elimination half-life of only approximately five minutes in circulation.[114] The metabolism of progesterone is complex, and it may form as many as 35 different unconjugated metabolites when it is ingested orally.[116][118] Progesterone is highly susceptible to enzymatic reduction via reductases and hydroxysteroid dehydrogenases because of its double bond (between the C4 and C5 positions) and its two ketones (at the C3 and C20 positions).[116]

The major metabolic pathway of progesterone is reduction by 5α-reductase[77] and 5β-reductase, into the dihydrogenated 5α-dihydroprogesterone and 5β-dihydroprogesterone, respectively.[115][116][119][120] This is followed by the further reduction of these metabolites via 3α-hydroxysteroid dehydrogenase and 3β-hydroxysteroid dehydrogenase into the tetrahydrogenated allopregnanolone, pregnanolone, isopregnanolone, and epipregnanolone.[121][115][116][119] Subsequently, 20α-hydroxysteroid dehydrogenase and 20β-hydroxysteroid dehydrogenase reduce these metabolites to form the corresponding hexahydrogenated pregnanediols (eight different isomers in total),[115][120] which are then conjugated via glucuronidation and/or sulfation, released from the liver into circulation, and excreted by the kidneys into the urine.[114][116] The major metabolite of progesterone in the urine is the 3α,5β,20α isomer of pregnanediol glucuronide, which has been found to constitute 15‍–‍30% of an injection of progesterone.[17][122] Other metabolites of progesterone formed by the enzymes in this pathway include 3α-dihydroprogesterone, 3β-dihydroprogesterone, 20α-dihydroprogesterone, and 20β-dihydroprogesterone, as well as various combination products of the enzymes aside from those already mentioned.[17][116][122][123] Progesterone can also first be hydroxylated (see below) and then reduced.[116] Endogenous progesterone is metabolized approximately 50% into 5α-dihydroprogesterone in the corpus luteum, 35% into 3β-dihydroprogesterone in the liver, and 10% into 20α-dihydroprogesterone.[124]

Relatively small portions of progesterone are hydroxylated via 17α-hydroxylase (CYP17A1) and 21-hydroxylase (CYP21A2), into 17α-hydroxyprogesterone and 11-deoxycorticosterone (21-hydroxyprogesterone), respectively,[118] and pregnanetriols are formed secondarily to 17α-hydroxylation.[125][126] Even smaller amounts of progesterone may also be hydroxylated via 11β-hydroxylase (CYP11B1) and, to a lesser extent, via aldosterone synthase (CYP11B2) into 11β-hydroxyprogesterone.[127][128][44] In addition, progesterone can be hydroxylated in the liver by other cytochrome P450 enzymes that are not steroid-specific.[129] Catalyzed mainly by CYP3A4, 6β-Hydroxylation is the major transformation and is responsible for approximately 70% of cytochrome P450-mediated progesterone metabolism.[129] Other routes include 6α-, 16α-, and 16β-hydroxylation.[116] However, treatment of women with ketoconazole (a strong CYP3A4 inhibitor) had minimal effects on progesterone levels, producing only a slight and non-significant increase, suggesting that cytochrome P450 enzymes play only a small role in progesterone metabolism.[130]

Metabolism of progesterone in humans[131]
The image above contains clickable links
This diagram illustrates the metabolic pathways involved in the metabolism of progesterone in humans. In addition to the transformations shown in the diagram, conjugation (specifically glucuronidation and sulfation) occurs with metabolites of progesterone that have one or more available hydroxyl (–OH) groups.

Levels

[edit]
Progesterone levels across the menstrual cycle in normally cycling and ovulatory women.[132] The horizontal lines are the mean integrated levels for each curve; the vertical line is mid-cycle.

Relatively low during the preovulatory phase of the menstrual cycle, progesterone levels rise after ovulation and are elevated during the luteal phase, as shown in the diagram. Progesterone levels tend to be less than 2 ng/mL prior to ovulation and greater than 5 ng/mL after ovulation. If pregnancy occurs, human chorionic gonadotropin is released, maintaining the corpus luteum and allowing it to maintain levels of progesterone. Between seven and nine weeks gestation, the placenta begins to produce progesterone in place of the corpus luteum in a process called the luteal-placental shift.[133]

After the luteal-placental shift, progesterone levels start to rise further and may reach 100 to 200 ng/mL at term. Whether a decrease in progesterone levels is critical for the initiation of labor has been argued and may be species-specific. After delivery of the placenta and during lactation, progesterone levels are very low.[citation needed]

Progesterone levels are low in children and postmenopausal people.[134] Adult males have levels similar to those in women during the follicular phase of the menstrual cycle.

Endogenous progesterone production rates and plasma progesterone levels
Group P4 production P4 levels
Prepubertal children ND 0.06–0.5 ng/mL
Pubertal girls
  Tanner stage I (childhood)
  Tanner stage II (ages 8–12)
  Tanner stage III (ages 10–13)
  Tanner stage IV (ages 11–14)
  Tanner stage V (ages 12–15)
    Follicular phase (days 1–14)
    Luteal phase (days 15–28)
 
ND
ND
ND
ND
 
ND
ND
 
0.22 (<0.10–0.32) ng/mL
0.30 (0.10–0.51) ng/mL
0.36 (0.10–0.75) ng/mL
1.75 (<0.10–25.0) ng/mL
 
0.35 (0.13–0.75) ng/mL
2.0–25.0 ng/mL
Premenopausal women
  Follicular phase (days 1–14)
  Luteal phase (days 15–28)
  Oral contraceptive (anovulatory)
 
0.75–5.4 mg/day
15–50 mg/day
ND
 
0.02–1.2 ng/mL
4–30 ng/mL
0.1–0.3 ng/mL
Postmenopausal women
Oophorectomized women
Oophorectomized and adrenalectomized women
ND
1.2 mg/day
<0.3 mg/day
0.03–0.3 ng/mL
0.39 ng/mL
ND
Pregnant women
  First trimester (weeks 1–12)
  Second trimester (weeks 13–26)
  Third trimester (weeks 27–40)
  Postpartum (at 24 hours)
 
55 mg/day
92–100 mg/day
190–563 mg/day
ND
 
9–75 ng/mL
17–146 ng/mL
55–255 ng/mL
19 ng/mL
Men 0.75–3 mg/day 0.1–0.3 ng/mL
Notes: Mean levels are given as a single value and ranges are given after in parentheses. Sources: [131][135][136][137][138][139][140][141][142]

Ranges

[edit]

Blood test results should always be interpreted using the reference ranges provided by the laboratory that performed the results. Example reference ranges are listed below.

Person type Reference range for blood test
Lower limit Upper limit Unit
Female - menstrual cycle (see diagram below)
Female - postmenopausal <0.2[143] 1[143] ng/mL
<0.6[144] 3[144] nmol/L
Female on oral contraceptives 0.34[143] 0.92[143] ng/mL
1.1[144] 2.9[144] nmol/L
Males 16 years 0.27[143] 0.9[143] ng/mL
0.86[144] 2.9[144] nmol/L
Female or male 1–9 years 0.1[143] 4.1[143] or 4.5[143] ng/mL
0.3[144] 13[144] nmol/L
Reference ranges for the blood content of progesterone during the menstrual cycle
Progesterone levels during the menstrual cycle[145]
• The ranges denoted By biological stage may be used in closely monitored menstrual cycles in regard to other markers of its biological progression, with the time scale being compressed or stretched to how much faster or slower, respectively, the cycle progresses compared to an average cycle.
• The ranges denoted Inter-cycle variability are more appropriate to use in non-monitored cycles with only the beginning of menstruation known, but where the woman accurately knows her average cycle lengths and time of ovulation, and that they are somewhat averagely regular, with the time scale being compressed or stretched to how much a woman's average cycle length is shorter or longer, respectively, than the average of the population.
• The ranges denoted Inter-woman variability are more appropriate to use when the average cycle lengths and time of ovulation are unknown, but only the beginning of menstruation is given.

Sources

[edit]

Animal

[edit]

Progesterone is produced in high amounts in the ovaries (by the corpus luteum) from the onset of puberty to menopause. It is produced in smaller amounts by the adrenal glands after the onset of adrenarche in both males and females. To a lesser extent, progesterone is produced in nervous tissue, especially in the brain, and also in adipose tissue (fat).[citation needed]

During human pregnancy, progesterone is produced in increasingly high amounts by the ovaries and placenta. At first, the source is the corpus luteum that has been "rescued" by the presence of human chorionic gonadotropin (hCG) from the conceptus. However, after the eighth week, production of progesterone shifts to the placenta which utilizes maternal cholesterol as the initial substrate, and most of the produced progesterone enters the maternal circulation, but some is picked up by the fetal circulation and used as substrate for fetal corticosteroids. At term, the placenta produces about 250 mg progesterone per day.[citation needed]

An additional animal source of progesterone is milk products. After consumption of milk products the level of bioavailable progesterone goes up.[146]

Plants

[edit]

Progesterone has been positively identified in the plant Juglans regia, a species of walnut.[147] In addition, progesterone-like steroids are found in the plant Dioscorea mexicana, part of the yam family native to Mexico.[148] Dioscorea mexicana contains a steroid called diosgenin which is taken from the plant and converted into progesterone.[149] Diosgenin and progesterone are also found in other Dioscorea species, as well as in other plants that are not closely related, such as fenugreek.

Another plant that contains substances readily convertible to progesterone is Dioscorea pseudojaponica, native to Taiwan. Research has shown that the Taiwanese yam contains saponins—steroids that can be converted to diosgenin and thence to progesterone.[150]

Many other Dioscorea species of the yam family contain steroidal substances from which progesterone can be produced. Among the more notable of these are Dioscorea villosa and Dioscorea polygonoides. One study showed that the Dioscorea villosa contains 3.5% diosgenin.[151] Dioscorea polygonoides has been found to contain 2.64% diosgenin, as shown by gas chromatography-mass spectrometry.[152] Many of the Dioscorea species that originate from the yam family grow in countries with tropical and subtropical climates.[153]

Medical use

[edit]

Progesterone is used as a medication. It is used in combination with estrogens mainly in hormone therapy for menopausal symptoms and low sex hormone levels.[118][154] It may also be used alone to treat menopausal symptoms. Studies have shown that transdermal progesterone (skin patch) and oral micronized progesterone are effective treatments for certain symptoms of menopause such as hot flashes and night sweats, otherwise referred to as vasomotor symptoms or VMS.[155]

It is also used to support pregnancy and fertility and to treat gynecological disorders.[156][157][158][159] Progesterone has been shown to prevent miscarriage in those with vaginal bleeding early in their current pregnancy and having a previous history of miscarriage.[160] Progesterone can be taken by mouth, through the vagina, and by injection into muscle or fat, among other routes.[118]

Chemistry

[edit]
A sample of progesterone

Progesterone is a naturally occurring pregnane steroid and is also known as pregn-4-ene-3,20-dione.[161][162] It has a double bond (4-ene) between the C4 and C5 positions, and two ketone groups (3,20-dione), one at the C3 position and the other at the C20 position.[161][162]

Synthesis

[edit]

Progesterone is commercially produced by semisynthesis. Two main routes are used: one from yam diosgenin first pioneered by Marker in 1940, and one based on soy phytosterols scaled up in the 1970s. Additional (not necessarily economical) semisyntheses of progesterone have also been reported starting from a variety of steroids. For the example, cortisone can be simultaneously deoxygenated at the C-17 and C-21 position by treatment with iodotrimethylsilane in chloroform to produce 11-keto-progesterone (ketogestin), which in turn can be reduced at position-11 to yield progesterone.[163]

Marker semisynthesis

[edit]

An economical semisynthesis of progesterone from the plant steroid diosgenin isolated from yams was developed by Russell Marker in 1940 for the Parke-Davis pharmaceutical company.[164] This synthesis is known as the Marker degradation.

The Marker semisynthesis of progesterone from diosgenin[164]

The 16-DPA intermediate is important to the synthesis of many other medically important steroids. A very similar approach can produce 16-DPA from solanine.[165]

Soy semisynthesis

[edit]

Progesterone can also be made from the stigmasterol found in soybean oil also. c.f. Percy Julian.

Stigmasterol to progesterone synthesis[166][167][168][169][170]

Total synthesis

[edit]
The Johnson total synthesis of progesterone[171]

A total synthesis of progesterone was reported in 1971 by William S. Johnson.[171] The synthesis begins with reacting the phosphonium salt 7 with phenyl lithium to produce the phosphonium ylide 8. The ylide 8 is reacted with an aldehyde to produce the alkene 9. The ketal protecting groups of 9 are hydrolyzed to produce the diketone 10, which in turn is cyclized to form the cyclopentenone 11. The ketone of 11 is reacted with methyl lithium to yield the tertiary alcohol 12, which in turn is treated with acid to produce the tertiary cation 13. The key step of the synthesis is the π-cation cyclization of 13 in which the B-, C-, and D-rings of the steroid are simultaneously formed to produce 14. This step resembles the cationic cyclization reaction used in the biosynthesis of steroids and hence is referred to as biomimetic. In the next step the enol orthoester is hydrolyzed to produce the ketone 15. The cyclopentene A-ring is then opened by oxidizing with ozone to produce 16. Finally, the diketone 17 undergoes an intramolecular aldol condensation by treating with aqueous potassium hydroxide to produce progesterone.[171]

History

[edit]

George W. Corner and Willard M. Allen discovered the hormonal action of progesterone in 1929.[17][172][173][174] By 1931–1932, nearly pure crystalline material of high progestational activity had been isolated from the corpus luteum of animals; by 1934, pure crystalline progesterone had been refined and obtained, and the chemical structure of progesterone was determined.[17][173] This was achieved by Adolf Butenandt at the Chemisches Institut of Gdańsk Technical University in Danzig, who extracted this new compound from several thousand liters of urine.[175]

Chemical synthesis of progesterone from stigmasterol and pregnanediol was accomplished later that year.[173][176] Up to this point, progesterone, known generically as corpus luteum hormone, had been being referred to by several groups by different names, including corporin, lutein, luteosterone, and progestin.[17][177] In 1935, at the time of the Second International Conference on the Standardization of Sex Hormones in London, England, a compromise was reached between the groups, and the name 'progesterone' (progestational steroidal ketone) was created.[17][178]

Veterinary use

[edit]

The use of progesterone tests in dog breeding to pinpoint ovulation is becoming more widely used. There are several tests available, the most reliable being a blood test with the blood sample drawn by a veterinarian and sent to a lab for processing. Results can usually be obtained within 24 to 72 hours. The rationale for using progesterone tests is that increased numbers begin in close proximity to preovulatory surge in gonadotrophins and continue through ovulation and estrus. When progesterone levels reach certain levels they can signal the stage of estrus the female is. Prediction of birth date of the pending litter can be very accurate if ovulation date is known. Puppies deliver within a day or two of nine weeks gestation in most cases. It is not possible to determine pregnancy using progesterone tests once a breeding has taken place, however. This is due to the fact that, in dogs, progesterone levels remain elevated throughout the estrus period.[179]

Pricing

[edit]

Pricing for progesterone can vary depending location, insurance coverage, discount coupons, quantity, shortages, manufacturers, brand or generic versions, different pharmacies, and so on. As of 2023, 30 capsules of 100 mg of the generic version, Progesterone, from CVS Pharmacy is around $40 without any discounts or insurance applied. The brand version, Prometrium, is around $450 for 30 capsules without any discounts or insurance applied.[180] In comparison, Walgreens offers 30 capsules of 100 mg in the generic version for $51 without insurance or coupons applied. The brand name costs around $431 for 30 capsules of 100 mg.[181]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
Progesterone is an endogenous with the molecular formula C₂₁H₃₀O₂, derived from , that plays a central role in reproductive , including the of the , preparation of the for , and maintenance of . It is primarily synthesized in the ovaries by the following , with additional production from the , testes in males (in smaller amounts), and the during , where it reaches peak levels to support fetal development. Chemically classified as a , progesterone exerts its effects by binding to progesterone receptors in target tissues, influencing and cellular processes essential for and beyond. In the , progesterone levels rise after under the influence of , transforming the from a proliferative to a secretory state by promoting glandular development and vascularization, which prepares it for potential implantation. If does not occur, declining progesterone triggers ; however, in early , it sustains the and later the to prevent and support embryogenesis, while also contributing to alveolar development for . Beyond , progesterone modulates the hypothalamic-pituitary-adrenal axis, exhibits neuroprotective effects in the brain, and influences and mood regulation through its metabolite , a . Clinically, progesterone and its synthetic analogs (progestins) are used in to counteract estrogen-induced in postmenopausal women, as contraceptives to inhibit , and in treatments for conditions like threatened , , and certain hormone-sensitive cancers. Levels vary across life stages: low in childhood, peaking during the (typically 2-25 ng/mL) and much higher during (up to 290 ng/mL in the third trimester), and declining post-menopause, with testing primarily via blood to assess fertility, ovarian function, or hormonal imbalances. Progesterone was first isolated in 1934 from the , a discovery that advanced understanding of and .

Biological functions

Hormonal interactions

Progesterone plays a central role in the hypothalamic-pituitary-ovarian axis during the , primarily exerting on (GnRH), (LH), and (FSH) secretion, in contrast to the biphasic effects of . In the , low progesterone levels allow rising to initially provide , suppressing GnRH and pulses to maintain early follicular development. As peaks mid-cycle, it switches to , triggering a surge in GnRH and LH that induces . Post-ovulation, progesterone from the dominates, reinforcing on the hypothalamus and pituitary to inhibit GnRH pulsatility and reduce LH and FSH secretion, thereby preventing further follicular maturation during the . In uterine preparation for implantation, progesterone synergizes with to promote endometrial proliferation and differentiation while also antagonizing certain estrogen-driven effects to establish receptivity. initially stimulates endometrial growth and vascularization during the proliferative phase, but rising progesterone in the secretory phase induces secretory transformation, , and immune modulation necessary for attachment. This synergy is evident in the coordinated expression of progesterone receptors (PR) and receptors (ER), where progesterone enhances ER activity for stromal remodeling but antagonizes estrogen's mitogenic effects on epithelial cells to create a narrow window of implantation (days 20-24 of the cycle). Disruptions in this balance, such as progesterone resistance, can impair receptivity and lead to implantation failure. Progesterone modulates and activity through its affinity for the (MR), acting as a competitive to and aldosterone. With binding affinity similar to aldosterone, progesterone inhibits MR activation in target tissues like the and vasculature, counteracting sodium retention and potassium excretion promoted by aldosterone during high-progesterone states such as . This antagonism helps maintain , though elevated progesterone can also influence feedback indirectly by altering hypothalamic-pituitary-adrenal axis sensitivity without directly binding receptors. The progesterone-to-estrogen ratio varies markedly across the and , reflecting their dynamic interplay. In the , progesterone levels remain low (<1 ng/mL) relative to rising estradiol (20-400 pg/mL), yielding a low ratio that favors estrogen dominance. During the luteal phase, progesterone surges to 5-20 ng/mL while estradiol stabilizes at 50-250 pg/mL, increasing the ratio to approximately 20-100:1, which sustains endometrial support. In , both hormones rise dramatically—progesterone to 100-200 ng/mL and estradiol to >10 ng/mL by term—but the ratio shifts to around 10-20:1, ensuring progesterone's primacy for maintaining .

Early sexual differentiation

In males, the regression of the Müllerian ducts, which would otherwise form the female reproductive tract, is primarily driven by (AMH) secreted by Sertoli cells in the developing testes starting around gestational week 8. Progesterone enhances AMH's regressive effects on the Müllerian ducts through direct interactions, as demonstrated in studies where progesterone at concentrations of 10^{-6} M potentiated AMH activity, leading to more complete ductal degeneration. This enhancement occurs in conjunction with rising levels, which stabilize the male phenotype, during the critical differentiation window of weeks 8 to 12 in when internal genitalia form. In females, the absence of androgens prevents stabilization of the Wolffian ducts, while the lack of AMH allows the Müllerian ducts to persist and differentiate into the fallopian tubes, , and upper during the same gestational weeks 8 to 12. Although this development proceeds largely as a default pathway without active hormonal promotion, progesterone levels from the contribute to the early embryonic environment that supports Müllerian duct maintenance in the absence of regressive signals from androgens or AMH. Animal models provide evidence for progesterone's influence on , particularly through disruptions observed in exposure and genetic studies. In progesterone knockout (PRKO) mice, while gross genital tract anatomy forms normally, altered progesterone signaling leads to impaired reproductive tract maturation and function, highlighting its role in fine-tuning differentiation processes. These findings from and models underscore progesterone's modulatory effects on early , often via interactions with pathways.

Reproductive system

Progesterone plays a central role in preparing the for by inducing of the endometrial stromal cells, a process essential for implantation. During the of the , rising progesterone levels from the transform the proliferative into a secretory state, promoting vascular remodeling, immune modulation, and nutrient provision to support the implanted . This decidual reaction involves the expression of progesterone receptors in stromal cells, which trigger morphological changes such as cellular enlargement and the secretion of and other factors that create a receptive environment for implantation. In maintaining pregnancy, progesterone inhibits uterine contractions by relaxing the myometrium and suppressing inflammatory pathways that could lead to preterm labor or miscarriage. It achieves this through negative regulation of contraction-associated proteins like connexin-43 and oxytocin receptors, while enhancing the expression of relaxin and other quiescence-promoting factors in the uterine smooth muscle. This inhibitory effect is particularly critical in the first trimester, where progesterone maintains low vascular tone and prevents spontaneous contractions until the placenta assumes hormone production. The balance between progesterone and estrogen further ensures uterine quiescence, with progesterone dominating to override estrogen's potential stimulatory effects on contractility. Progesterone also regulates ovulation timing by providing on the hypothalamic-pituitary axis post-, suppressing further (LH) surges to prevent multiple ovulations in a single cycle. Secreted by the , it reduces GnRH pulse frequency and inhibits LH release from the pituitary, thereby supporting the and sustaining endometrial receptivity for up to 14 days if implantation occurs. This feedback mechanism is vital for maintenance in early , where (hCG) from the embryo prolongs its function until placental progesterone production takes over. Low levels of progesterone in women commonly cause irregular menstrual periods, difficulty conceiving, and abnormal uterine bleeding, reflecting disruptions in cycle regulation, endometrial preparation, and implantation support. In males, progesterone modulates function and through local synthesis in testicular and prostatic tissues. Within the and male reproductive tract, it activates progesterone receptors to oppose estrogen effects, influencing epithelial and proliferation and potentially exerting a protective role against by counteracting androgen-driven growth. Progesterone also affects by regulating sperm capacitation, , and motility, with intratesticular levels promoting germ cell maturation while high exogenous levels can suppress gonadotropin-driven sperm production. These effects highlight progesterone's broader involvement in male reproductive physiology, including modulation of steroidogenesis.

Breasts

Progesterone, in conjunction with , plays a key role in promoting ductal during and early reproductive life, facilitating the elongation and branching of mammary ducts to establish the foundational architecture of tissue. primarily drives the initial ductal elongation, while progesterone induces side-branching and further through mechanisms involving factors such as and Wnt4, which stimulate epithelial and invasion into the surrounding stroma. During pregnancy, progesterone is essential for the stimulation of lobuloalveolar development, transforming the ductal network into a structure capable of production by promoting the proliferation and differentiation of alveolar epithelial cells. This process involves progesterone receptor-mediated signaling that coordinates with and other hormones to induce alveolar budding and secretory differentiation, ensuring the mammary gland's readiness for . Prolonged exposure to progesterone, particularly in combined estrogen-progestin (HRT), is associated with an increased risk of , primarily through mechanisms that enhance and disrupt normal . Synthetic progestins in HRT can activate progesterone receptors to promote the expansion of stem and progenitor cells in tissue, leading to higher incidence rates compared to estrogen-only , with risks escalating with duration of use beyond five years. In contrast, endogenous progesterone exposure through full-term exerts protective effects against by inducing terminal differentiation of mammary epithelial cells, which reduces the proliferative potential of stem and populations. This differentiation, mediated by progesterone signaling during , alters profiles to favor a more mature, less susceptible epithelial state, thereby lowering lifetime risk, especially for estrogen receptor-positive tumors.

Skin health

Progesterone modulates sebum production in the skin, with mixed effects stemming from its partial anti-androgenic properties, including inhibition of , which reduces the conversion of testosterone to the more potent (DHT), a key stimulator of activity. However, elevated progesterone levels overall stimulate , increasing sebum secretion and contributing to conditions like acne vulgaris, particularly during the of the when hyperseborrhea can exacerbate inflammation and comedone formation. Regarding collagen synthesis and wound healing, progesterone influences dermal , often in synergy with , to promote remodeling. In ovariectomized models, sequential administration of followed by progesterone enhances biosynthesis and increases fibroblast expression in abdominal , supporting tissue repair processes. Progesterone also stimulates migration , facilitating epithelialization during wound closure and aiding in the restoration of integrity without excessive scarring. However, in postmenopausal contexts, combined -progestin does not significantly alter content or synthesis rates compared to alone, suggesting a modulatory rather than stimulatory role for progesterone. Progesterone plays a notable role in and , particularly during where it is termed chloasma gravidarum. Elevated progesterone levels in the third trimester, alongside and , heighten activity and expression, leading to symmetric hyperpigmented patches on sun-exposed areas like the face. Postmenopausal women receiving progesterone supplementation develop more frequently than those on alone, underscoring progesterone's direct stimulatory effect on production independent of . Progesterone exerts anti-inflammatory effects that bolster skin barrier function by binding to progesterone receptors on and immune cells, thereby suppressing pro-inflammatory release such as TNF-α and modulating immune responses. This activity helps maintain epidermal integrity, reduces , and prevents barrier disruption in inflammatory dermatoses, contributing to overall during hormonal fluctuations.

Sexuality

Progesterone plays a significant role in modulating sexual desire and behavior across the menstrual cycle in women. During the follicular phase, rising estradiol levels are associated with increased sexual motivation, while the subsequent elevation in progesterone during the luteal phase correlates with a decline in subjective sexual desire. This negative effect of progesterone on sexual motivation is thought to reflect an adaptive mechanism to reduce mating efforts when conception is unlikely, as supported by evolutionary models of hormonal influences on female sexuality. Human studies tracking daily hormone levels and self-reported desire over multiple cycles confirm that progesterone mediates the post-ovulatory drop in libido, with no significant between-women differences attributable to baseline hormone profiles. Additionally, peri-ovulatory increases in sexual activity align with low progesterone levels, further highlighting its inhibitory role during the luteal phase. In , elevated progesterone levels contribute to suppressed , particularly as concentrations rise progressively across trimesters. This suppression is evident in reduced reported by many women, potentially due to progesterone's counteraction of estrogen's pro-sexual effects and its promotion of offspring-focused attention over sexual stimuli. effects underlie this modulation, as progesterone influences neural circuits involved in reward and motivation, shifting behavioral priorities toward maintenance. Postpartum progesterone withdrawal can paradoxically delay recovery despite its overall inhibitory influence during . Progesterone modulates sexual receptivity primarily through its receptors in the , particularly in the ventromedial nucleus (VMH), as demonstrated in models. In estradiol-primed female rats, progesterone binding to hypothalamic receptors facilitates and other receptive behaviors via both genomic (nuclear receptor-mediated gene transcription) and nongenomic (membrane-initiated rapid signaling) pathways. Activation of progesterone receptor-expressing neurons in the VMH is required for the expression of female sexual behaviors, with periodic remodeling of these circuits timing receptivity to the . These mechanisms highlight the as a key site for progesterone's central regulation of sexual responsiveness. Animal models, such as domestic sheep, reveal correlations between prenatal hormonal influences and . Approximately 8% of rams exhibit exclusive male-oriented preferences, associated with female-like features in the of the , which develops under prenatal hormonal influences, primarily androgens. These findings from sheep models provide insights into potential hormonal contributions to across species.

Nervous system

Progesterone exerts neuromodulatory effects in the primarily through its metabolite , which acts as a positive of GABA_A receptors. This interaction enhances inhibitory , contributing to effects by reducing neuronal excitability and promoting a calming influence on brain activity. Clinical and preclinical studies have demonstrated that elevated levels, derived from progesterone, correlate with decreased anxiety behaviors in various models. Progesterone also supports myelination and neuronal survival, essential processes for maintaining neural integrity. In the peripheral nervous system, progesterone stimulates Schwann cells to form myelin sheaths around axons, enhancing the rate of myelin formation in cocultures of neurons and glial cells. Furthermore, progesterone and its derivatives promote neuronal viability in the central and peripheral s, protecting against degeneration by modulating anti-apoptotic pathways and reducing . Recent research highlights the synergistic neuroprotective roles of estrogen and progesterone in aging and Alzheimer's disease. A 2024 study in animal models of Alzheimer's showed that progesterone administration improved cognitive performance and reduced neuroinflammation, with interactions with estrogen's neuroprotection being mixed—some studies showing enhancement and others indicating potential antagonism. In males, progesterone activates progesterone receptors in the brain to oppose estrogen's regulatory actions, such as by down-regulating estrogen receptors in regions like the periventricular preoptic area. This suggests potential therapeutic applications for hormone combinations in mitigating age-related cognitive decline. In human studies, associations between endogenous progesterone levels and cognitive performance are inconsistent; positive associations with verbal memory and global cognition have been observed in early postmenopausal women (within 6 years of menopause), but findings are null in older postmenopausal women, with no consistent evidence of clinically important effects overall. No direct associations between progesterone and intelligence quotient (IQ) in adults have been established. Progesterone influences -wake cycles and mood stabilization via its properties mediated by allopregnanolone's GABA_A modulation. Administration of progesterone reduces wakefulness during EEG recordings in postmenopausal women, increasing total sleep time without impairing cognitive function. These effects contribute to mood stabilization by alleviating symptoms of anxiety and , particularly during hormonal fluctuations in the . Conversely, low progesterone levels in women are associated with mood changes such as anxiety or depression, as well as headaches.

Brain damage

Progesterone exhibits neuroprotective properties in models of (TBI), primarily through the reduction of and inflammation. In rodent studies, administration of progesterone following TBI significantly decreases swelling by modulating expression and fluid dynamics, thereby limiting secondary tissue damage. Similarly, progesterone attenuates neuroinflammatory responses by suppressing pro-inflammatory production, such as interleukin-1β and tumor necrosis factor-α, in both male and female subjects. These effects have been consistently observed across multiple experimental paradigms, including fluid percussion and controlled cortical impact models, highlighting progesterone's potential to mitigate the acute consequences of brain trauma. The proposed mechanisms underlying these protective actions include antioxidant activity, inhibition of , and stabilization of the blood-brain barrier (BBB). Progesterone's antioxidant effects involve scavenging and upregulating endogenous antioxidants like , which counteract post-injury. It also inhibits apoptotic pathways by modulating proteins and caspase-3 activation, preserving neuronal viability. Additionally, progesterone reinforces BBB integrity by enhancing proteins such as and claudin-5, preventing leakage and further formation. Clinical trials evaluating progesterone for TBI and have yielded mixed results up to 2023, with preclinical promise not fully translating to human outcomes. Phase II trials, such as the Progesterone for Traumatic Brain Injury (ProTECT) studies, suggested improved functional recovery and reduced mortality, but larger phase III trials like ProTECT III and reported no significant benefits over in reducing mortality or improving neurological outcomes. Ongoing preclinical and early-phase studies as of 2025 continue to investigate progesterone's role in ischemic , focusing on optimized dosing and timing to enhance efficacy. Gender differences in progesterone's efficacy may arise from variations in endogenous hormone levels, with females often showing greater neuroprotection due to higher baseline progesterone concentrations during reproductive cycles. In animal models, exogenous progesterone provides more pronounced benefits in males, who have lower endogenous levels, compared to females where it may interact with fluctuating ovarian hormones. These disparities underscore the need for sex-specific considerations in therapeutic applications.

Addiction

Progesterone modulates release in the through its receptors, thereby influencing reward processing and potentially reducing the reinforcing effects of addictive substances. In animal models, progesterone and its metabolites have been shown to attenuate self-administration of , alcohol, and . For instance, progesterone administration reduces intake and cocaine-seeking behavior in female rats, while its metabolite decreases self-administration in male rats by enhancing inhibition in reward pathways. In women, vulnerability to addiction relapse exhibits cycle-dependent patterns, with increased risk during the late when progesterone levels are declining. This phase is associated with heightened craving and withdrawal symptoms for substances like and , potentially due to reduced progesterone-mediated dampening of activity. Progesterone interacts with systems to modulate pain perception and reward, often through its neuroactive metabolite , which enhances mu-opioid receptor signaling and reduces opioid-induced reward in preclinical studies. These interactions may contribute to progesterone's protective effects against by altering pain-reward balance.

Other effects

Progesterone exerts significant immunomodulatory effects, particularly in promoting maternal-fetal tolerance during by suppressing proinflammatory T-cell activity. It inhibits the proliferation and production of Th1 and Th17 cells while enhancing regulatory T cells (Tregs), which dampen immune responses at the maternal-fetal interface to prevent rejection of the . This suppression of T-cell activation is mediated through progesterone receptors on immune cells, leading to reduced interferon-gamma and interleukin-17 secretion, thereby fostering an environment essential for successful . Additionally, progesterone promotes the expansion of decidual Tregs, further contributing to by limiting cytotoxic T-cell responses. In skeletal health, progesterone supports maintenance by stimulating activity and differentiation. It binds to progesterone receptors on , promoting their proliferation and enhancing bone formation through increased expression of osteogenic factors such as and . This action counters , particularly in premenopausal women, and has been shown to increase bone mineral density in trabecular sites like the spine when progesterone levels are adequate. Studies indicate that progesterone's osteoanabolic effects help mitigate the risk of by favoring -mediated matrix deposition over in mesenchymal stem cells. Progesterone influences cardiovascular function through vasodilatory and anti-atherogenic mechanisms. It stimulates endothelial (eNOS) expression, leading to production that induces and improves vascular relaxation, particularly in coronary and peripheral arteries. Furthermore, progesterone exhibits anti-atherogenic properties by reducing (LDL) oxidation, decreasing lipid accumulation in arterial walls, and modulating inflammatory responses in the to inhibit plaque formation. These effects contribute to overall vascular protection, though they may vary in combination with . Recent research has highlighted progesterone's role in facilitating cancer immune evasion within tumor microenvironments, drawing parallels to its immunosuppressive functions in pregnancy. In breast cancer models, progesterone receptor signaling downregulates major histocompatibility complex class I (MHC-I) expression on tumor cells, impairing CD8+ T-cell recognition and promoting immune escape. Similarly, progestogens upregulate B7-H4, an immune checkpoint ligand, in ovarian and endometrial tumors, which suppresses antitumor T-cell activity and enhances tumor progression by mimicking pregnancy-associated tolerance.00652-4) A 2024 study further demonstrated that progesterone reprograms the tumor microenvironment to share immunosuppressive features with the fetoplacental unit, including elevated Treg infiltration and reduced natural killer cell cytotoxicity, thereby fostering therapy resistance.

Biochemistry

Biosynthesis

Progesterone is synthesized endogenously through the steroidogenesis pathway, beginning with as the precursor substrate. The initial and rate-limiting step involves the of into the mitochondria, facilitated by the (StAR), followed by its conversion to by the side-chain cleavage enzyme (CYP11A1). This cleavage removes the side chain from , yielding . Subsequently, is transformed into progesterone by the 3β-hydroxysteroid dehydrogenase (3β-HSD), which oxidizes the 3β-hydroxyl group to a keto group while reducing NAD⁺ to NADH. The biochemical reaction catalyzed by 3β-HSD can be represented as: [Pregnenolone](/page/Pregnenolone)+NAD+Progesterone+NADH+H+\text{[Pregnenolone](/page/Pregnenolone)} + \text{NAD}^+ \rightarrow \text{Progesterone} + \text{NADH} + \text{H}^+ This step occurs primarily in the and is essential for progesterone production across steroidogenic tissues. Multiple isoforms of 3β-HSD exist, with 3β-HSD2 being predominant in the adrenals, ovaries, and . The primary sites of progesterone biosynthesis are the in the ovaries, the during , and the . In non-pregnant individuals, the , formed post-ovulation, serves as the main source during the of the , producing up to 25 mg of progesterone daily. The contributes smaller amounts, approximately 1-2 mg per day, serving as a precursor for other steroids. During , the becomes the dominant site after approximately 10 weeks, synthesizing large quantities to maintain , with production reaching 250-500 mg per day by term. Biosynthesis is tightly regulated by hormonal signals. In the , (LH) from the stimulates progesterone production by activating the cAMP-protein kinase A pathway, which upregulates and key enzymes like CYP11A1 and 3β-HSD, ensuring peak output during the mid-luteal phase. During , placental progesterone synthesis shifts to largely autocrine regulation independent of maternal or fetal endocrine inputs, though initial support comes from (hCG) and local placental factors such as (CRH) and , which modulate enzyme expression to sustain elevated levels.

Distribution

Progesterone circulates in the plasma bound to carrier proteins, which facilitate its transport while regulating its . Approximately 80% of circulating progesterone is bound to with low affinity, 15-20% binds to corticosteroid-binding globulin (CBG) with high affinity, less than 1% to (SHBG), and the remaining 1–2% exists in the unbound, free form that is biologically active. This binding distribution helps maintain stable levels and prevents rapid clearance, with the free fraction available for into tissues. Due to its inherent as a , progesterone readily diffuses across lipid bilayers of cell membranes via , independent of specific carriers or energy-dependent mechanisms. This property enables progesterone to penetrate various barriers, including the blood-brain barrier, where it can influence neuronal function directly. Similarly, during , progesterone crosses the by , contributing to fetal exposure, though the extent of maternal-to-fetal transfer is limited to about 1% of circulating maternal levels as the increasingly synthesizes its own progesterone. Tissue-specific concentrations of progesterone fluctuate in response to physiological demands, particularly across the . In the , for instance, myometrial progesterone levels are markedly elevated during the (ranging from 2.06 to 14.85 ng/g wet weight) compared to the , reflecting targeted accumulation to support endometrial preparation for implantation. These variations underscore progesterone's role in localized signaling at reproductive target sites.

Metabolism

Progesterone undergoes rapid metabolism primarily in the liver, where it is transformed into various inactive and active metabolites to facilitate its elimination from the body. The of unbound progesterone in circulation is approximately 5 minutes, reflecting its swift hepatic clearance and limiting its persistence in blood. This rapid turnover ensures that progesterone's physiological effects are tightly regulated, with over 90% of the hormone metabolized during the first pass through the liver. A key step in progesterone's involves hepatic reduction of its Δ4-3-keto structure by 5α-reductases and 5β-reductases, leading to the formation of 5α-dihydroprogesterone and 5β-dihydroprogesterone, respectively. These intermediates are further reduced, primarily via 3α-hydroxysteroid dehydrogenase activity, to yield pregnanediol (5β-pregnane-3α,20α-diol), a major urinary metabolite that accounts for about 12% of progesterone's metabolic products. Among the notable metabolites are (3α-hydroxy-5α-pregnan-20-one) and (3α-hydroxy-5β-pregnan-20-one), which are neuroactive neurosteroids derived from the respective dihydroprogesterones and exhibit potent modulatory effects on GABA_A receptors in the . For excretion, progesterone metabolites such as pregnanediol are conjugated primarily with in the liver, forming water-soluble glucuronides that are efficiently eliminated via the , accounting for roughly 80% of total . This conjugation enhances renal clearance and prevents in the intestines, ensuring the complete removal of progesterone-derived compounds from the body.

Levels

Progesterone concentrations in the vary significantly across the , , and other physiological states, providing key insights into reproductive health. In non-pregnant women, serum progesterone levels are typically low during the , ranging from 0.1 to 1.5 ng/mL, reflecting minimal ovarian production before . Following , levels rise sharply in the to 2 to 25 ng/mL, driven by the , and remain elevated for about 10 to 14 days before declining if does not occur. In men and postmenopausal women, baseline levels are consistently low, generally below 1 ng/mL. During pregnancy, levels increase dramatically to support implantation and fetal development, starting at 10 to 44 ng/mL in the first trimester and progressively rising to 65 to 290 ng/mL by the third trimester, with peaks often observed around 32 weeks. This escalation is essential for maintaining uterine quiescence and preventing . Progesterone exhibits diurnal variations, with concentrations showing a : levels are lowest in the early morning ( around 8:00 a.m.) and peak toward midnight, particularly pronounced in the and . Age-related changes include a gradual decline post-reproduction, with postmenopausal levels stabilizing at under 0.2 to 1 ng/mL due to ovarian . These variations can be influenced by factors such as , as detailed in the distribution section. Serum progesterone is commonly measured using immunoassays, such as enzyme-linked immunosorbent assays () or chemiluminescent immunoassays, which are rapid but may suffer from and variability. For higher accuracy and specificity, liquid chromatography-tandem mass spectrometry (LC-MS/MS) serves as the reference method, particularly useful in and when immunoassay results are ambiguous. Clinically, progesterone levels hold diagnostic value: in the mid-, concentrations above 5 ng/mL confirm , while levels below 3 ng/mL suggest or deficiency, often indicating risks or conditions like . Elevated levels beyond normal ranges may signal or molar disease, whereas low levels in early (<10 ng/mL) are associated with increased risk.
Physiological StateTypical Serum Progesterone Range (ng/mL)Source
0.1–1.5NCBI StatPearls
2–25NCBI StatPearls
First Trimester Pregnancy10–44Healthline
Third Trimester Pregnancy65–290Healthline
Postmenopausal<1Medscape

Sources

Progesterone occurs naturally in various animal tissues and products, particularly those from pregnant mammals, where it plays a key role in maintaining pregnancy. In dairy animals like cows, progesterone concentrations are notably higher in milk from pregnant individuals, often used as a diagnostic marker for pregnancy status, with levels reflecting luteal activity. Meat and other edible tissues contain lower amounts compared to milk, but progesterone is detectable in muscle and organs, especially from gestating females where corpus luteum tissues exhibit elevated concentrations to support fetal development. In plants, true progesterone is present only in trace quantities, as confirmed by gas chromatography-mass spectrometry analyses across higher plant species, with detections in reproductive structures such as pollen and fruits. For instance, progesterone has been quantified in pollen grains and fruit tissues of various plants, where it may influence growth processes, though at levels far below those in animals. Progesterone-like compounds, such as diosgenin—a steroidal sapogenin precursor to progesterone—are more abundant in certain plant tubers, notably those of Dioscorea species (wild yams), but these do not directly provide bioavailable progesterone. Dietary intake of progesterone from these animal and plant sources is negligible in humans, contributing less than 1% of endogenous production even from high-consumption items like full-fat , and thus not serving as a meaningful supplement source. This limited exogenous contribution underscores that human progesterone levels are primarily regulated by internal from in gonadal and adrenal tissues. Progesterone's presence across vertebrates highlights its evolutionary conservation, functioning as a fundamental in reproductive from to mammals.

Medical uses

Gynecological and obstetric applications

Progesterone plays a crucial role in gynecological and obstetric applications, particularly in supporting treatments and maintaining . In assisted reproductive technologies such as fertilization (IVF), progesterone is administered to provide support, compensating for the lack of endogenous progesterone production after ovarian stimulation. This supplementation is typically delivered via intramuscular injections or vaginal suppositories, with studies demonstrating improved implantation rates and live birth outcomes when initiated post-ovum retrieval. For the prevention of preterm birth, intramuscular 17α-hydroxyprogesterone caproate (17-OHPC) was previously used in women with a history of spontaneous preterm delivery based on early studies like Meis et al. (2003), which reported a 34% reduction in recurrent preterm birth risk. However, following the PROLONG trial (2020) showing no efficacy, 17-OHPC is no longer recommended by ACOG and was withdrawn from the market in 2023. Current guidelines recommend vaginal progesterone, such as 90 mg daily gel, for high-risk women with a singleton pregnancy and short cervix (<25 mm) measured between 16 and 24 weeks of gestation, which meta-analyses indicate reduces the risk of preterm birth by approximately 30-40%. Preterm birth is associated with lower average IQ in offspring, but follow-up from RCTs shows no net cognitive benefit from progesterone supplementation itself, and it is not recommended for low-risk pregnancies or for IQ enhancement purposes. Progesterone is also used in the treatment of threatened , where vaginal administration of micronized progesterone (e.g., 400 mg daily) has been associated with reduced rates in women presenting with in early . A of randomized trials supports this approach, indicating a significant decrease in loss without increased adverse effects. In the management of , progesterone or progestins are employed to suppress endometrial tissue growth and alleviate symptoms like and , often as part of combined oral contraceptives or standalone therapy. Clinical guidelines endorse progestin-only treatments for patients intolerant to , with evidence from systematic reviews showing symptom relief in up to 70% of cases. Standard dosing for support in IVF includes 200-400 mg daily of vaginal micronized progesterone suppositories, divided into two or three doses, continued until the or through the first trimester if is confirmed. This regimen balances efficacy with tolerability, as higher doses may increase local side effects like irritation.

In postmenopausal (HRT), progesterone is commonly combined with to mitigate the risk of in women with an intact . alone can stimulate endometrial proliferation, potentially leading to hyperplasia and increased risk, but the addition of progesterone counteracts this by inducing secretory changes in the . This is recommended for women experiencing menopausal symptoms such as issues and vaginal . Oral micronized progesterone, typically administered at doses of 100-200 mg nightly, is a preferred bioidentical option for this purpose due to its natural structure and pharmacokinetic profile. Continuous daily dosing at 100 mg or sequential dosing at 200 mg for 12-14 days per month effectively protects against without the androgenic or side effects often seen with synthetic progestins like . Compared to synthetic progestins, micronized progesterone demonstrates a more favorable safety profile, including less adverse impact on cholesterol levels and a lower associated risk of in HRT users. However, progesterone cream is generally not recommended for individuals with or history of breast cancer, particularly hormone receptor-positive (ER+ or PR+) tumors, as it may be absorbed systemically and stimulate growth in sensitive cells or increase recurrence risk. Major guidelines from NAMS and ASCO advise against systemic hormone therapy including progesterone in such cases, favoring non-hormonal options for menopausal symptoms; consult oncologist for individualized assessment. Note that while bioidentical progesterone may pose lower risk than synthetics in healthy women per some studies, safety lacks support in breast cancer contexts. In transgender feminizing hormone therapy, progesterone is increasingly incorporated alongside estrogen and anti-androgens to enhance breast development. During female puberty, progesterone contributes to mammary gland maturation by promoting ductal branching and lobular-alveolar growth, and its addition in transgender care aims to replicate this process for more complete breast maturation. Clinical studies indicate that progesterone supplementation leads to greater patient satisfaction with breast development, with one prospective study reporting 53.8% satisfaction at 6 months versus 19.6% in standard estrogen-only regimens. A 2025 survey of transgender women using progestogens found that 79.6% perceived improvements in breast development, supporting its role in optimizing feminization outcomes. Recent reviews affirm the cardiovascular safety of long-term HRT incorporating micronized progesterone, particularly when combined with . Unlike oral estrogen-progestin combinations, which may elevate risks of venous and coronary heart disease, micronized progesterone with shows no increased cardiovascular events and may confer protective benefits in younger postmenopausal women or those early in . These formulations avoid first-pass liver , reducing prothrombotic effects observed with synthetic progestins in earlier trials.

Other therapeutic uses

Progesterone has been investigated for its neuroprotective properties in (TBI) and , primarily due to its ability to reduce , neuronal loss, and in preclinical models. However, large-scale clinical trials, such as the ProTECT III trial completed in 2014, failed to demonstrate significant improvements in functional outcomes or mortality rates compared to in patients with moderate to severe TBI. Despite these setbacks, post-hoc analyses and smaller studies up to 2023 have identified subgroups, such as those with lower lesion volumes and elevated biomarkers like GFAP and UCH-L1, where progesterone showed potential benefits, prompting ongoing trials as of 2025 focused on ischemic and refined patient selection criteria. In , recent research highlights progesterone's role in immune modulation, particularly how (PR) signaling downregulates (MHC) class I expression on tumor cells, thereby promoting immune evasion and reducing sensitivity to therapies like anti-LAG3 checkpoint inhibitors. This mechanism, elucidated in 2024 studies, suggests potential applications for modulators as adjuvants in hormone receptor-positive s to enhance antitumor immune responses when combined with . For instance, selective modulators like have shown promise in preclinical models for disrupting these evasion pathways, though clinical translation remains experimental. Progesterone is used therapeutically for catamenial , a condition where seizures exacerbate during specific phases due to fluctuations in sex , with supplementation aimed at stabilizing progesterone levels to counteract estrogen's proconvulsant effects. Clinical studies, including a 2013 trial in women with intractable catamenial , reported frequency reductions of up to 50% with cyclic progesterone therapy, though results vary by pattern (perimenstrual or periovulatory). Similarly, for (PMDD), progesterone metabolites like modulate GABA receptors to alleviate mood symptoms; intermittent dosing has shown efficacy in reducing and anxiety in affected women, as supported by preclinical and small-scale clinical data linking steroid imbalances to PMDD etiology. During the early 2020s, progesterone was explored experimentally for mitigating -related , leveraging its immunosuppressive and effects to dampen storms. A 2021 pilot trial in 40 men with severe found that progesterone supplementation alongside standard care improved oxygenation and reduced dependence, with no adverse hormonal effects. Further mechanistic studies from 2023 indicate progesterone modulates pathways like to limit pro-inflammatory release, supporting its potential in hyperinflammatory phases of the disease, though larger randomized trials are needed to confirm .

Chemistry

Structure and properties

Progesterone is a C21 with the molecular formula C21H30O2, its preferred IUPAC name is pregn-4-ene-3,20-dione, and its systematic IUPAC name with stereochemistry is (8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopentaphenanthren-3-one. It features a skeleton with oxo () groups at positions 3 and 20, and a between carbons 4 and 5. The molecular structure is a pregnane steroid with four fused rings (A/B/C six-membered, D five-membered), a double bond between C4 and C5, ketone groups at C3 and C20 (acetyl side chain at C17), and methyl groups at C10 and C13. It has six chiral centers with the natural stereochemistry: 8β, 9α, 10β, 13β, 14α, 17β (corresponding to the listed S/R designations). This structure places it within the class of progestogens, distinguishing it from other s like estrogens or androgens through its specific saturation and arrangement on the four-ring cyclopentanoperhydrophenanthrene core. Physically, progesterone appears as a white crystalline powder that is insoluble in but soluble in organic solvents such as and acetone. It has a of 128°C and exhibits high , reflected by its (logP) of 3.87, which facilitates its membrane permeability and distribution in lipid-rich tissues. Progesterone demonstrates high binding affinity to the (PR), specifically its two main isoforms, PR-A and PR-B, which share identical ligand-binding domains and thus equivalent affinity for the hormone. This selective interaction is crucial for its , with dissociation constants in the nanomolar range for both isoforms. In its metabolites, progesterone often undergoes reduction to yield compounds with a 5β-pregnane configuration, such as 5β-dihydroprogesterone, where the A/B ring junction adopts a cis orientation characteristic of this . This 5β-reduction contrasts with the 5α-series and influences the pharmacological properties of these derivatives.

Synthesis

Progesterone is primarily produced through semisynthetic methods derived from plant sterols for both laboratory and industrial purposes. The Marker degradation, developed by Russell E. Marker in , represents a foundational semisynthetic route starting from diosgenin, a steroidal sapogenin extracted from the tubers of Mexican yams such as . This process involves initial of the spiroketal at C-22 and C-26 to form diosgenin diacetate, followed by oxidative cleavage with to degrade the and yield progesterone, achieving high yields in a multi-step sequence that revolutionized production. An alternative semisynthetic pathway utilizes , a byproduct of refining. Pioneered by Percy L. Julian in the 1940s, this method entails chemical or oxidative degradation of the stigmasterol side chain to produce 22-dihydrostigmasterol or related intermediates, followed by microbial with like Mycobacterium species to introduce the Δ4-3-keto functionality and complete the conversion to progesterone. This soy-based route has become prominent due to the abundant and low-cost availability of stigmasterol. Total synthesis of progesterone, independent of natural sterols, was first accomplished by William S. Johnson in 1971 via a biomimetic approach featuring polyolefinic cyclization to construct the ring system from simple acyclic precursors, establishing through cationic intermediates. Modern asymmetric total syntheses employ chiral catalysts and organometallic reagents for enantioselective ring formation, such as in routes using palladium-catalyzed allylic alkylations or enzymatic resolutions, though these remain laboratory-scale due to their complexity and cost compared to . In contemporary industrial production, plant sterol-based predominates for pharmaceutical-grade progesterone, favoring microbial biotransformations of or sitosterol mixtures over diosgenin routes for greater , , and reduced environmental impact, as exemplified by processes using recombinant Mycolicibacterium strains expressing mammalian steroidogenic enzymes.

History and society

Discovery and development

The existence of a progestational hormone from the was first demonstrated in 1928 by George W. Corner and Willard M. Allen through bioassays in rabbits. , a key essential for , was first isolated in pure crystalline form in 1934 from the of sow ovaries by German biochemist and his collaborators, who processed approximately 625 kg of sow ovaries from about 50,000 sows to yield 20 mg of the compound. This isolation was part of a concerted effort by multiple research groups that year, including those led by Karl Slotta in , Oskar Wintersteiner and Willard Allen , and Max Hartmann and Arthur Wettstein in , marking the culmination of earlier work on luteal hormones dating back to the 1920s. Concurrently, American chemist Russell Marker contributed to early advancements in progesterone research through his work on steroid extractions and degradations at Pennsylvania State College, though his major impact came later in scalable synthesis methods. The of progesterone was elucidated shortly after its isolation, revealing it as a 21-carbon derivative with a group at C-20 and a between C-4 and C-5 in the nucleus. Butenandt's team confirmed this structure through degradative analysis and partial synthesis, establishing progesterone as the active principle responsible for maintaining by promoting endometrial secretory changes and inhibiting . The was named "progesterone" to reflect its progestational role—derived from "pro" (for) and "gestare" (to carry or bear in )—and initially termed "progestin" to denote its pregnancy-sustaining activity, distinguishing it from other luteal extracts like the earlier identified "prolan." Butenandt's pioneering contributions to sex hormone research, including the isolation and structural determination of progesterone alongside and estrone, earned him half of the 1939 , shared with Leopold Ruzicka for related work on male hormones; the award was deferred until 1949 due to . This recognition underscored the foundational impact of these discoveries on , enabling subsequent therapeutic applications. Building on natural progesterone's limitations—such as poor oral —researchers in the developed synthetic oral progestins to enable reliable contraception. In 1951, and colleagues at in synthesized norethindrone (also known as norethisterone), a 19-norsteroid derivative that retained potent progestational activity while being orally active, achieved through ethynylation at C-17 and removal of the C-19 methyl group. This breakthrough, patented in 1952, paved the way for combined oral contraceptives, with norethindrone first incorporated into clinical formulations by the late , revolutionizing .

Veterinary applications

Progesterone is widely used in to synchronize estrus in , facilitating and improving breeding efficiency in beef and dairy operations. Intravaginal progesterone-releasing devices, such as the Controlled Internal Drug Release (CIDR) insert containing 1.38 grams of progesterone, are inserted for 7 days to suppress follicular development and , followed by removal to induce a synchronized estrus wave typically within 2-5 days. This approach, often combined with (GnRH) or prostaglandin F2α (PGF2α), achieves estrus synchronization rates exceeding 80% in cycling cows and heifers, enhancing conception rates post-insemination. In equine reproductive management, progesterone supplementation plays a key role in maintaining in mares, particularly those at risk of due to luteal insufficiency or induced luteolysis. Administration of progesterone via intramuscular injections (e.g., 150-300 mg daily) or oral progestins like altrenogest (0.044 mg/kg) supports endometrial progesterone levels, preventing premature luteolysis and reducing incidence by up to 50% in high-risk from day 70 onward. Long-acting formulations, such as progesterone in poly(D,L-lactide) microspheres, have been effective in sustaining for 30-60 days post-treatment in ovariectomized models, mimicking natural function. Progesterone has historically been employed as a hormonal growth promotant in , particularly , to enhance feed efficiency and carcass weight gain by modulating anabolic processes. However, its use for this purpose is banned in the since 1981 due to concerns over potential hormone residues in and products, which could pose risks to consumers. In contrast, implants containing progesterone are approved by the for growth promotion in , with residue levels monitored to remain below established safety thresholds.

Pricing and availability

Generic progesterone for oral (HRT) typically costs between $10 and $50 per month for a standard 100 mg dose, based on 2023-2025 pricing data from major pharmacies. This range accounts for variations in supply duration and generic formulations, with a 90-day supply of 100 mg capsules often available for around $14.50 to $50. Progesterone is available over-the-counter in some bioidentical forms, such as topical creams derived from plant sources like wild yams, which are marketed for menopausal symptom relief without a prescription. However, prescription is required for pharmaceutical-grade forms, including oral capsules (e.g., micronized progesterone like Prometrium) and injectables, to ensure regulated dosing and . Ongoing debates about the risks and benefits of HRT, including progesterone, have influenced coverage, with concerns over and cardiovascular risks from earlier studies leading to restrictive policies in some regions. In the , while standard HRT is often partially covered, bioidentical progesterone formulations are frequently classified as non-essential or "" treatments, resulting in higher out-of-pocket costs or denials. Recent reassessments affirming low overall risks for short-term use have prompted some insurers to expand coverage, but variability persists. Global disparities in progesterone access are pronounced, with costs in the remaining high due to market-driven pricing, while European countries often subsidize HRT through systems, reducing monthly expenses to under $10 for generics. In developing countries, generic progesterone is significantly cheaper—sometimes as low as $0.28 per capsule via international pharmacies—facilitating broader availability but raising concerns about unregulated quality.

References

Add your contribution
Related Hubs
User Avatar
No comments yet.